Common Concern
Blood in the Urine
Blood in the urine, also called hematuria, is a symptom rather than a diagnosis. It is often not cancer, but it is important to evaluate it carefully so important causes are not missed.
Hematuria at a Glance
Two Main Types
- Visible blood in the urine (gross hematuria)
- Blood found only under the microscope (microscopic hematuria)
Why It Matters
- Many causes are not dangerous
- Some causes are important to find
- Bleeding can come and go
- Risk helps guide the workup
Common Evaluation
- Urine testing
- Risk review
- Imaging when appropriate
- Cystoscopy when indicated
The Most Important Thing to Remember
Hematuria is not a diagnosis. It is a clue. The goal is to understand where the blood may be coming from and whether it points to something that needs treatment.
Many evaluations are reassuring, but blood in the urine should not be ignored simply because it stops or because there is no pain.
What Is Hematuria?
Hematuria means blood in the urine. Sometimes patients see red, pink, or tea-colored urine. Other times, the urine looks normal and blood is found only under the microscope.
The first step is to clarify whether the blood is visible or found only under the microscope. Both can matter, but they are not always evaluated in exactly the same way.
What Happens at the First Visit?
A hematuria visit is less about one test and more about understanding the full story. The details help determine how aggressive the evaluation needs to be.
Confirm the Finding
For microscopic hematuria, the finding is first confirmed by seeing red blood cells on microscopy, not just a positive dipstick.
Understand the Pattern
Important details include whether the blood was visible or painful, whether it happened once or repeatedly, and whether it has resolved.
Review Risk Factors
Age, smoking history, symptoms, stone history, infections, medications, and prior urologic history all help guide the workup.
Choose the Next Step
Some patients need a complete evaluation. Others may reasonably start with repeat urine testing or a more limited approach. The guideline provides a framework, while symptoms, the clinical scenario, and patient concerns also inform the decision.
Visible Blood Should Not Be Ignored
One episode of painless visible blood in the urine should never be ignored, even if it completely resolves. It may be the only early warning sign a patient receives.
Some patients diagnosed with advanced bladder cancer later remember one isolated episode of visible blood months or years earlier that was never evaluated. That does not mean visible blood always means cancer. It means the symptom deserves respect.
When there is no clear cause, visible blood typically requires a complete evaluation. This generally includes imaging of the kidneys and ureters—usually a CT urogram when it can be obtained—along with cystoscopy and urine cytology.
A complete evaluation may sometimes be deferred when there is a convincing, documented explanation, such as confirmed passage of a kidney stone. That decision is individualized. Persistent or recurrent bleeding, or other concerning risk factors, should bring the question back to the table.
How Risk Guides the Workup
The recently updated AUA risk-based guideline helps guide the evaluation of microscopic hematuria. The amount of blood seen under the microscope, whether it persists, age, smoking history, urinary symptoms, prior visible blood, and other clinical factors help determine the level of concern.
Depending on that risk, the next step may be a repeat urinalysis, renal and bladder ultrasound, CT urography, cystoscopy, or selected additional urine testing. Not everyone needs every test. At the same time, unusual symptoms, the broader clinical picture, or a patient's concerns may reasonably support additional evaluation after discussion.
The goal is to use the guideline as a framework without making the visit formulaic: avoid missing important disease while also avoiding testing that is unlikely to help.
What If There Is a Urinary Infection?
When urine testing confirms an infection, that is treated first because it is the established problem. After the infection has cleared, the urine can be rechecked under the microscope to confirm whether the blood also resolved.
What happens next depends on the repeat result and the broader picture. The discussion considers the patient's history, risk factors, symptoms, concerns, and whether further evaluation would add useful information.
How Testing Fits Together
Imaging and cystoscopy answer different questions. They complement one another when a complete hematuria evaluation is needed.
Urine Testing
Urinalysis with microscopy confirms whether blood is truly present. A urine culture may be used when infection is possible.
Imaging
Imaging evaluates the kidneys and ureters. For unexplained visible blood, this is usually a CT urogram when it can be safely obtained. The specific test may differ with kidney function, contrast limitations, risk, and clinical context.
Cystoscopy
Cystoscopy directly examines the bladder lining and urethra. It is the cornerstone of evaluation because the bladder lining is where urothelial cancer is most commonly found.
Additional Testing
Urine cytology is generally included in a complete evaluation for visible blood. Kidney function or urine protein testing may also be appropriate. Findings that suggest medical kidney disease may lead to nephrology evaluation.
What to Expect From Cystoscopy
Cystoscopy is often the part of the evaluation patients are most nervous about. The office procedure typically takes only a few minutes, local anesthetic jelly is used, and patients walk in and walk out.
After an uncomplicated office cystoscopy without sedation, most patients can typically drive themselves home, return to normal activities, and may experience mild burning, a small amount of blood, or some bladder pressure, urgency, and frequency. These symptoms usually settle within about 24 hours. Individual instructions may differ.
Fever or chills, inability to urinate, or heavy bleeding or clots are not expected and should prompt a call or urgent evaluation. Cystoscopy is important because imaging cannot always show what the bladder lining looks like.
After a Reassuring Evaluation
A normal cystoscopy and reassuring imaging are good news. Most patients do not need indefinite follow-up with a urologist after an appropriate negative evaluation.
Whether to repeat a urinalysis is individualized. An older patient with a substantial smoking history may benefit from another urine check in six to twelve months, while a younger low-risk patient may not need routine follow-up. New visible blood, a meaningful increase in microscopic blood, or new urinary symptoms should bring the question back to the table.
What About Blood Thinners?
One common question is whether the blood is "just from the blood thinner." Blood thinners can contribute to or worsen bleeding, but they should not automatically be assumed to be the entire explanation. They can also make an underlying problem, such as a bladder tumor or kidney stone, more likely to bleed and become noticeable.
That means patients on anticoagulants or antiplatelet medications still need an appropriate hematuria evaluation. Medication decisions should be individualized and coordinated with the prescribing clinician when needed.
Common Misconceptions
If the bleeding stopped, everything is fine.
Bleeding can be intermittent. The fact that it resolved does not always mean the underlying question has been answered.
A positive dipstick always means microscopic hematuria.
True microscopic hematuria is confirmed by seeing red blood cells under the microscope.
Blood thinners explain it away.
Blood thinners can reveal bleeding, but they do not remove the need to consider an underlying cause.
Imaging replaces cystoscopy.
Imaging looks at the kidneys and ureters. Cystoscopy looks directly at the bladder and urethra. They answer different questions.
The Goal
Blood in the urine is often not cancer, but it should not be ignored. The goal is to find important causes early while avoiding unnecessary testing in appropriately selected low-risk patients.